tweetindex
RU

Samuel Hume ✓

@DrSamuelBHume · joined 04 Jan 2019

Doctor, scientist | Trying to speed up science and solve disease

61 524Followers
1 604Following
4 439Posts total
216.2KViews on collected posts

Последние посты

@DrSamuelBHume Short term great, long-term studies needed for cancer risky 2.8K views · 21 likes · 0 reposts · 2 replies Open on X →
Presented recently at the American Diabetes Association: https://t.co/s0oQIfkkOS 5.5K views · 32 likes · 2 reposts · 0 replies Open on X →
Cool pre-clinical weight loss drug from Korea. It hits 4 receptors: GLP1 - GIP - human growth hormone (hGH) - activin type II receptor (ActRII). It ~matches tirzepatide for weight loss, with more fat loss and less lean mass loss. 99.5% of weight loss was fat: https://t.co/pXXn
127.4K views · 1K likes · 90 reposts · 33 replies Open on X →
"GPT-6 Astra saturates the eval" 4.5K views · 16 likes · 1 reposts · 1 replies Open on X →
How do GLP1s affect the musculoskeletal system? Bone? Mixed evidence, probably no effect Joints? Protects cartilage, probable direct effect Tendon? Anecdotal evidence of snapping Muscle? It is adaptive, not maladaptive, muscle loss @peterkcrane, founder of EnteloBio, explains: 5.8K views · 42 likes · 6 reposts · 5 replies Open on X →
Old female mice, equivalent to 60 year old humans, taking the GLP1 receptor agonist, semaglutide: - Move more, with better balance and coordination (protection against frailty?) - Have better cognitive function (perform better on tests of learning and memory) - Have better http 40.9K views · 375 likes · 55 reposts · 10 replies Open on X →
The ongoing Ebola outbreak has grown faster than any previous outbreak — but it MIGHT now be slowing down. https://t.co/i4adKwIHHE 2.9K views · 15 likes · 1 reposts · 0 replies Open on X →
This week in medicine 1. Revolution Medicines' daraxonrasib gets FDA-approved! 2. Moderna's personalized cancer vaccine succeeds in a phase 3 trial for melanoma 3. Nektar's Treg-boosting antibody treats eczema in a phase 2 trial 4. Researchers at the Universities of 26.3K views · 334 likes · 52 reposts · 17 replies Open on X →

На фоне аккаунтов своего размера

8 постов за последние 90 дней рядом с диапазоном 10K–100K подписчиков. показывается широко, но откликается мало кто.

Медианные просмотры5 668этот аккаунт924медиана для 10K–100K
Охват, %9.21%этот аккаунт3.62%медиана для 10K–100K
Вовлечённость, %0.86%этот аккаунт1.52%медиана для 10K–100K
ПоказательЭтот аккаунтМедиана для 10K–100KОтношение
Медианные просмотры на пост5 6689246.13×
Охват (просмотры ÷ подписчики)9.21%3.62%2.54×
Вовлечённость0.86%1.52%0.56×

Другие в этом диапазоне →   Сравнить с другим аккаунтом →   Как считаются эти ориентиры →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

26.3K30 Aug
2.9K1 Sep
40.9K2 Sep
5.8K
4.5K3 Sep
127.4K12 Sep
5.5K
2.8K

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.56%30 Aug
0.55%1 Sep
1.09%2 Sep
0.92%
0.40%3 Sep
0.90%12 Sep
0.61%
0.82%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes64.2%1 855 in total
Reposts7.2%207 in total
Replies2.4%68 in total
Quotes0.4%12 in total
Bookmarks25.9%747 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Похожие аккаунты